Key result
SCH 39370, a neutral endopeptidase inhibitor, decreased left ventricular pressures, improved cardiac function, and induced diuresis and natriuresis in rats with congestive heart failure.
Why the study?
Does SCH 39370 improve haemodynamic, renal, and hormonal parameters in rats with congestive heart failure?
Does SCH 39370 improve haemodynamic, renal, and hormonal parameters in rats with congestive heart failure?
NEP inhibition with SCH 39370 improves cardiac function and induces diuresis and natriuresis in a rat model of heart failure, suggesting therapeutic potential.
The acute hormonal, renal and haemodynamic effects of SCH 39370, a new neutral endopeptidase (NEP) inhibitor, were evaluated in rats with congestive heart failure (CHF) produced by coronary ligation. 2. Left ventricular systolic pressure and left ventricular end diastolic pressure were significantly decreased by SCH 39370 treatment. 3. SCH 39370 improved cardiac function by increasing cardiac index and decreasing total peripheral resistance. 4. SCH 39370 induced a transient but significant diuresis and natriuresis. 5. These effects were associated with significant increases in urinary atrial natriuretic peptide (ANP) and cyclic GMP excretion, but not with an increase in plasma ANP levels. 6. The results suggest that NEP inhibition may be a new therapeutic method for treating CHF possibly by potentiating the biological activities of endogenous ANP.
No takes yet. Share an insight, caveat, or question.
Murohara et al. (1992) studied Congestive heart failure. SCH 39370 was evaluated on Acute hormonal, renal and haemodynamic effects. SCH 39370, a neutral endopeptidase inhibitor, decreased left ventricular pressures, improved cardiac function, and induced diuresis and natriuresis in rats with congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: